Alaunos Therapeutics Inc. Common Stock (TCRT)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-style investor, I want understandable businesses with durable advantages, honest earnings, and a margin of safety. Alaunos fails most of those tests. It is a pre-clinical biopharmaceutical company with one employee, working on oral small-molecule therapies for obesity and metabolic disorders. In fiscal year 2025, the year ended 2025-12-31, it reported revenue of $5,000 and a net loss of $4.2 million. In fiscal year 2024, the year ended 2024-12-31, revenue was $10,000 with a $4.7 million net loss. In fiscal year 2023, the year ended 2023-12-31, revenue was $5,000 with a $4.7 million net loss. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $952,000 and diluted EPS was -$0.41. Trailing free cash flow was -$2.8 million, a FairStock FCF yield of -36.7%. At the 2026-10-13 close of $3.03, the market cap was $7.7 million. FairStock calculations show a negative P/E of -1.72, P/B of 11.65, ROE of -185.95%, ROCE of -81.13%, Piotroski F-Score of 3/9, and Altman Z-Score of -852.46. The FairStock Score is 22/100, and the computed Lynch category is none because the company lost money in each of the last four years. There is no evident moat: no approved product, negligible revenue, and one employee. Revenue growth is -25.00% and profit growth is -20.35%. Valuation rests on future pipeline hopes, not current earnings. I would treat this as speculation, not a Graham-style value investment.

In plain English: Alaunos Therapeutics is a very early-stage drug developer working on oral medicines for obesity and related metabolic disorders; it has no approved products and almost no revenue. The business looks weak financially, losing millions each year while bringing in only a few thousand dollars of revenue. At the 2026-10-13 close of $3.03, the price looks expensive relative to those tiny sales and ongoing losses, though biotech shares can move on trial news rather than current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer